134 related articles for article (PubMed ID: 36931171)
1. Complexity and diversity of FOXP3 isoforms: Novel insights into the regulation of the immune response in metastatic breast cancer.
Malla R; Adem M; Chakraborty A
Int Immunopharmacol; 2023 May; 118():110015. PubMed ID: 36931171
[TBL] [Abstract][Full Text] [Related]
2. Exploring the role CD163-labeled TAMs and FOXP3-labeled Tregs in different types of breast cancer: Reflections and putative benefits.
Shash LS; M Kamal KA; Abd Raboh NM
Indian J Pathol Microbiol; 2021; 64(1):28-37. PubMed ID: 33433406
[TBL] [Abstract][Full Text] [Related]
3. The expression of FOXP3 and its role in human cancers.
Jia H; Qi H; Gong Z; Yang S; Ren J; Liu Y; Li MY; Chen GG
Biochim Biophys Acta Rev Cancer; 2019 Jan; 1871(1):170-178. PubMed ID: 30630091
[TBL] [Abstract][Full Text] [Related]
4. Metastatic triple-negative breast cancers at first relapse have fewer tumor-infiltrating lymphocytes than their matched primary breast tumors: a pilot study.
Cimino-Mathews A; Ye X; Meeker A; Argani P; Emens LA
Hum Pathol; 2013 Oct; 44(10):2055-63. PubMed ID: 23701942
[TBL] [Abstract][Full Text] [Related]
5. FOXP3/HAT1 Axis Controls Treg Infiltration in the Tumor Microenvironment by Inducing CCR4 Expression in Breast Cancer.
Sarkar T; Dhar S; Chakraborty D; Pati S; Bose S; Panda AK; Basak U; Chakraborty S; Mukherjee S; Guin A; Jana K; Sarkar DK; Sa G
Front Immunol; 2022; 13():740588. PubMed ID: 35222362
[TBL] [Abstract][Full Text] [Related]
6. Metabolic regulation of forkhead box P3 alternative splicing isoforms and their impact on health and disease.
Luo Z; Zhang Y; Saleh QW; Zhang J; Zhu Z; Tepel M
Front Immunol; 2023; 14():1278560. PubMed ID: 37868998
[TBL] [Abstract][Full Text] [Related]
7. Association of Notch pathway down-regulation with Triple Negative/Basal-like breast carcinomas and high tumor-infiltrating FOXP3+ Tregs.
Ortiz-Martínez F; Gutiérrez-Aviñó FJ; Sanmartín E; Pomares-Navarro E; Villalba-Riquelme C; García-Martínez A; Lerma E; Peiró G
Exp Mol Pathol; 2016 Jun; 100(3):460-8. PubMed ID: 27118257
[TBL] [Abstract][Full Text] [Related]
8. Transcriptional regulation of FOXP3 requires integrated activation of both promoter and CNS regions in tumor-induced CD8
Chakraborty S; Panda AK; Bose S; Roy D; Kajal K; Guha D; Sa G
Sci Rep; 2017 May; 7(1):1628. PubMed ID: 28487507
[TBL] [Abstract][Full Text] [Related]
9. Human FOXP3 and tumour microenvironment.
Wang J; Gong R; Zhao C; Lei K; Sun X; Ren H
Immunology; 2023 Feb; 168(2):248-255. PubMed ID: 35689826
[TBL] [Abstract][Full Text] [Related]
10. FoxP3
Saleh R; Elkord E
Cancer Lett; 2020 Oct; 490():174-185. PubMed ID: 32721551
[TBL] [Abstract][Full Text] [Related]
11. Characterisation of Foxp3 splice variants in human CD4+ and CD8+ T cells--identification of Foxp3Δ7 in human regulatory T cells.
Kaur G; Goodall JC; Jarvis LB; Hill Gaston JS
Mol Immunol; 2010; 48(1-3):321-32. PubMed ID: 20688398
[TBL] [Abstract][Full Text] [Related]
12. Forced overexpression of either of the two common human Foxp3 isoforms can induce regulatory T cells from CD4(+)CD25(-) cells.
Aarts-Riemens T; Emmelot ME; Verdonck LF; Mutis T
Eur J Immunol; 2008 May; 38(5):1381-90. PubMed ID: 18412171
[TBL] [Abstract][Full Text] [Related]
13. Expression of B7-H3, a potential factor of tumor immune evasion in combination with the number of regulatory T cells, affects against recurrence-free survival in breast cancer patients.
Maeda N; Yoshimura K; Yamamoto S; Kuramasu A; Inoue M; Suzuki N; Watanabe Y; Maeda Y; Kamei R; Tsunedomi R; Shindo Y; Inui M; Tamada K; Yoshino S; Hazama S; Oka M
Ann Surg Oncol; 2014 Dec; 21 Suppl 4(Suppl 4):S546-54. PubMed ID: 24562936
[TBL] [Abstract][Full Text] [Related]
14. FOXP3+ Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy.
Ghebeh H; Barhoush E; Tulbah A; Elkum N; Al-Tweigeri T; Dermime S
BMC Cancer; 2008 Feb; 8():57. PubMed ID: 18294387
[TBL] [Abstract][Full Text] [Related]
15. Investigation on the regulatory T cells signature and relevant Foxp3/STAT3 axis in esophageal cancer.
Yang L; Zhao Q; Wang X; Pilapong C; Li Y; Zou J; Jin J; Rong J
Cancer Med; 2023 Feb; 12(4):4993-5008. PubMed ID: 36226375
[TBL] [Abstract][Full Text] [Related]
16. Proinflammatory cytokine interferon-γ and microbiome-derived metabolites dictate epigenetic switch between forkhead box protein 3 isoforms in coeliac disease.
Serena G; Yan S; Camhi S; Patel S; Lima RS; Sapone A; Leonard MM; Mukherjee R; Nath BJ; Lammers KM; Fasano A
Clin Exp Immunol; 2017 Mar; 187(3):490-506. PubMed ID: 27936497
[TBL] [Abstract][Full Text] [Related]
17. Higher densities of Foxp3
Yeong J; Thike AA; Lim JC; Lee B; Li H; Wong SC; Hue SS; Tan PH; Iqbal J
Breast Cancer Res Treat; 2017 May; 163(1):21-35. PubMed ID: 28233108
[TBL] [Abstract][Full Text] [Related]
18. Direct targeting of FOXP3 in Tregs with AZD8701, a novel antisense oligonucleotide to relieve immunosuppression in cancer.
Revenko A; Carnevalli LS; Sinclair C; Johnson B; Peter A; Taylor M; Hettrick L; Chapman M; Klein S; Solanki A; Gattis D; Watt A; Hughes AM; Magiera L; Kar G; Ireland L; Mele DA; Sah V; Singh M; Walton J; Mairesse M; King M; Edbrooke M; Lyne P; Barry ST; Fawell S; Goldberg FW; MacLeod AR
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35387780
[TBL] [Abstract][Full Text] [Related]
19. Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer.
Kim ST; Jeong H; Woo OH; Seo JH; Kim A; Lee ES; Shin SW; Kim YH; Kim JS; Park KH
Am J Clin Oncol; 2013 Jun; 36(3):224-31. PubMed ID: 22495453
[TBL] [Abstract][Full Text] [Related]
20. PTEN-deficient prostate cancer is associated with an immunosuppressive tumor microenvironment mediated by increased expression of IDO1 and infiltrating FoxP3+ T regulatory cells.
Vidotto T; Saggioro FP; Jamaspishvili T; Chesca DL; Picanço de Albuquerque CG; Reis RB; Graham CH; Berman DM; Siemens DR; Squire JA; Koti M
Prostate; 2019 Jun; 79(9):969-979. PubMed ID: 30999388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
